EUVIMEDEUVIMED entdecken
Crossref

3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations

AUDREY MARECHAL, MARTIN GAUDIER, OLIVIER SOULA, CLAIRE MÉGRET, SANA HAKIM, YOU-PING CHAN, ANNE-LISE GAFFURI, BAPTISTE PLANCQ, ALEXANDRE MARTIN, KARINE LELU, JEAN DUTREUIL, EMMANUEL DAUTY und 1 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-3104-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von AUDREY MARECHAL und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: AdoXLong technology is designed to deliver sustained peptide circulation for at least one month. This new long-acting peptide platform is based on a biocompatible polymer chemically linked to peptides of interest while maintaining their mechanism of action. AdoXLong was applied to semaglutide to develop a once-a-month formulation.

Methods

The bioactivity of AdoXLong Sema was determined in vitro by measuring cAMP production in GLP1-R overexpressing cells. Formulation was tested in rats following a subcutaneous injection. Plasma samples were analyzed by ELISA.

Results

In vitro, AdoXLong Sema demonstrates a high affinity to albumin. The intrinsic in vitro potency of GLP1-RA from AdoXLong Sema is well preserved and even slightly increased compared to semaglutide (Relative potency: 151%). A strong decrease of AdoXLong Sema in vitro potency is observed in the presence of human albumin, confirming its high affinity to albumin. Pharmacokinetic analysis of AdoXLong Sema after subcutaneous injection in rats shows an apparent half-life of 24h, i.e. 3.5 times that of semaglutide (Fig. 1).

Conclusion

These results indicate that AdoXLong Sema offers an effective strategy to extend the half-life and duration of action of semaglutide, potentially enabling once-monthly administration in humans. Disclosure A. Marechal: Employee; Current; ADOCIA. M. Gaudier: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. O. Soula: Board Member; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. Employee; Current; ADOCIA. C. Mégret: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. S. Hakim: Employee; Current; ADOCIA. Y. Chan: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. A. Gaffuri: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. B. Plancq: None. A. Martin: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. K. Lelu: Employee; Current; ADOCIA. J. Dutreuil: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. E. Dauty: Employee; Current; ADOCIA. U. Naessens: Employee; Current; ADOCIA.

Zitieren

APA

MARECHAL, A., GAUDIER, M., SOULA, O., MÉGRET, C., HAKIM, S., CHAN, Y., GAFFURI, A., PLANCQ, B., MARTIN, A., LELU, K., DUTREUIL, J., DAUTY, E., & NAESSENS, U. (2026). 3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3104-lb

Vancouver

MARECHAL A, GAUDIER M, SOULA O, MÉGRET C, HAKIM S, CHAN Y, et al. 3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3104-lb

BibTeX
@article{MARECHAL2026,
  author = {MARECHAL, AUDREY and GAUDIER, MARTIN and SOULA, OLIVIER and MÉGRET, CLAIRE and HAKIM, SANA and CHAN, YOU-PING and GAFFURI, ANNE-LISE and PLANCQ, BAPTISTE and MARTIN, ALEXANDRE and LELU, KARINE and DUTREUIL, JEAN and DAUTY, EMMANUEL and NAESSENS, ULYSSE},
  title = {3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-3104-lb}
}
Kostenlos starten →